PACIRA BIOSCIENCES, INC. Effective Income Tax Rate Reconciliation, Tax Credit, Percent
PACIRA BIOSCIENCES, INC. (PCRX) reported Effective Income Tax Rate Reconciliation, Tax Credit, Percent of -8.99% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits · last filed 2026-02-26
- PACIRA BIOSCIENCES, INC. effective income tax rate reconciliation, tax credit, percent for fiscal 2024 was -8.99%, a 266.79% decline from fiscal 2023.
- PACIRA BIOSCIENCES, INC. effective income tax rate reconciliation, tax credit, percent for fiscal 2023 was 5.39%, a 77.90% decline from fiscal 2022.
- PACIRA BIOSCIENCES, INC. effective income tax rate reconciliation, tax credit, percent for fiscal 2022 was 24.39%, a 713.00% increase from fiscal 2021.
- PACIRA BIOSCIENCES, INC. effective income tax rate reconciliation, tax credit, percent for fiscal 2021 was 3.00%, a 62.12% decline from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Percent 12 month | Effective Income Tax Rate Reconciliation, Tax Credit, Percent 12 month as first filed |
|---|---|---|
| 2024-12-31 | -8.99% 10-K · filed 2026-02-26 | |
| 2023-12-31 | 5.39% 10-K · filed 2026-02-26 | |
| 2022-12-31 | 24.39% 10-K · filed 2025-02-27 | 19.11% 10-K · filed 2023-02-28 |
| 2021-12-31 | 3.00% 10-K · filed 2024-02-29 | |
| 2020-12-31 | 7.92% 10-K · filed 2023-02-28 | |
| 2019-12-31 | -19.93% 10-K · filed 2022-02-28 | |
| 2018-12-31 | -700.35% 10-K · filed 2021-03-01 | |
| 2017-12-31 | -4.96% 10-K · filed 2020-02-21 | |
| 2016-12-31 | -8.77% 10-K · filed 2019-02-28 | |
| 2015-12-31 | 30.63% 10-K · filed 2018-02-28 | -30.63% 10-K · filed 2016-02-25 |
| 2014-12-31 | -5.49% 10-K · filed 2017-03-01 | 5.49% 10-K · filed 2015-02-24 |
| 2013-12-31 | 1.69% 10-K · filed 2016-02-25 | |
| 2012-12-31 | 0.00% 10-K · filed 2015-02-24 | |
| 2011-12-31 | 0.13% 10-K · filed 2014-02-25 | -0.13% 10-K · filed 2013-03-07 |
| 2010-12-31 | -0.18% 10-K · filed 2013-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |